Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
15 studies found for:    INCB039110
Show Display Options
Rank Status Study
1 Active, not recruiting An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post Polycythemia Vera Fibrosis;   Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: INCB039110
2 Recruiting An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: INCB039110;   Drug: Osimertinib
3 Completed A Study of Escalating Doses of INCB039110 Administered Orally in Patients With Plaque Psoriasis
Condition: Chronic Plaque Psoriasis
Interventions: Drug: INCB039110;   Drug: Placebo
4 Active, not recruiting Study of INCB039110 in Combination With Corticosteroids for the Treatment of Acute GVHD
Condition: Acute Graft Versus Host Disease
Interventions: Drug: INCB039110 (200 mg);   Drug: INCB039110 (300 mg);   Drug: prednisone or methylprednisolone (corticosteroids)
5 Not yet recruiting A Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: INCB039110;   Drug: ibrutinib
6 Active, not recruiting Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Conditions: Metastatic Cancer;   Metastatic Pancreatic Cancer
Interventions: Drug: INCB039110;   Drug: Gemcitabine;   Drug: nab-paclitaxel;   Drug: filgrastim
7 Completed A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: INCB039110;   Drug: INCB039110 Placebo
8 Terminated Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: INCB039110;   Drug: Placebo;   Drug: docetaxel
9 Active, not recruiting INCB040093 and INCB040093 Combined With INCB039110 in Relapsed/Refractory Hodgkin Lymphoma
Conditions: Refractory Hodgkin Lymphoma;   Recurrent Adult Hodgkin's Lymphoma
Interventions: Drug: INCB040093 Monotherapy;   Drug: INCB040093;   Drug: INCB039110
10 Withdrawn INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Conditions: Carcinoma;   Non Small Cell Lung Cancer
Interventions: Drug: INCB039110;   Drug: erlotinib;   Drug: placebo
11 Recruiting A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B-Cell Malignancies
Condition: B-Cell Malignancies
Interventions: Drug: INCB050465;   Drug: INCB039110;   Drug: Rituximab;   Drug: Ifosfamide;   Drug: Carboplatin;   Drug: Etoposide
12 Recruiting Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Conditions: Advanced Solid Tumors;   Endometrial Cancer;   Melanoma;   Microsatellite Unstable (MSI) Colorectal Cancer;   MMR-deficient Tumors;   Non-small Cell Lung Cancer;   Renal Cell Carcinoma;   Head and Neck Squamous Cell Carcinoma;   Triple Negative Breast Cancer;   Transitional Cell Carcinoma of the Genitourinary Tract;   Pancreatic Ductal Adenocarcinoma
Interventions: Drug: Pembrolizumab;   Drug: INCB039110;   Drug: INCB050465
13 Recruiting INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors
Condition: Advanced Solid Tumors
Interventions: Drug: INCB039110;   Drug: Epacadostat;   Drug: INCB050465
14 Active, not recruiting Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
Condition: B-cell Malignancies
Interventions: Drug: INCB040093;   Drug: INCB040093 + INCB039110
15 Not yet recruiting Relieving Chronic Itch: Oral Medication
Condition: Pruritis
Intervention: Drug: INCB039110

Study has passed its completion date and status has not been verified in more than two years.